TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

SHANGHAI HENGRUI

OncologyMetabolicNeurology
Generics

SHANGHAI HENGRUI is a generic drug manufacturer focused on Oncology, Metabolic, Neurology.

2015
Since
2
Drugs
-
Trials
3
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

SEVOFLURANE 2025-10-02
Labeling
DESFLURANE 2024-11-07
Labeling
SEVOFLURANE 2024-08-30
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 68%
0 drugs Phase 3: 2 Phase 2: 4 Phase 1: 22
Metabolic 11%
0 drugs Phase 3: 1 Phase 1: 2
Neurology 7%
0 drugs Phase 2: 1 Phase 1: 2
Respiratory 7%
0 drugs Phase 2: 1 Phase 1: 2
Gastroenterology 7%
0 drugs Phase 3: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Takeda big-pharma
Oncology, Gastroenterology, Neurology, Metabolic
EISAI INC big-pharma
Oncology, Neurology, Metabolic, Respiratory, Gastroenterology
Amgen biotech
Oncology, Metabolic, Gastroenterology, Neurology
EMD SERONO INC biotech
Oncology, Neurology, Metabolic, Gastroenterology
GSK big-pharma
Respiratory, Oncology, Neurology